News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TONIX Pharmaceuticals, Inc. Announces The Enrollment Of Completers From The BESTFIT Trial Into A 12-Month Open-Label Extension Study



12/10/2013 9:11:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, announced today that it is enrolling subjects into an open-label extension (OLE) study to the BESTFIT trial of TNX-102 2.8 mg sublingual tablet (SL) in fibromyalgia (FM).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES